• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

NEW GENRE Audio English-Spanish – Series C: e-Books on Cancer & Oncology

Series C: e-Books on Cancer & Oncology NEW GENRE Audio English-Spanish

 

View on Amazon.com

 

Spanish Series C

Serie C: libros electrónicos acerca del cáncer y la oncología

(2 book series) Kindle Edition

Series URL

https://www.amazon.com/dp/B0BQHMRK3C?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn

Volume Titles & URL on Amazon.com

Volumen 1

Biología y genómica del cáncer para el diagnóstico de la enfermedad (Serie C: libros electrónicos acerca del cáncer y la oncología nº 1)

(Spanish Edition) Kindle Edition

http://www.amazon.com/dp/B0BQHFXKHH

 

Volumen 2

Tratamientos contra el cáncer: Metabólicos, genómicos, intervencionistas, inmunoterapia y nanotecnología para la administración de tratamientos (Serie … y la oncología nº 2)

(Spanish Edition) Kindle Edition

http://www.amazon.com/dp/B0BQTM44SM

 

 

Volume’s Date of Publication, Price, Audio

Spanish Series C

Date of Publication

Spanish Edition Price

 

$231

 

English Edition

Price

 

Audio

Volumen 1

12/18/2022

156

75

No

Volumen 2

12/21/2022

75

100

No

 

Volume One

View on Amazon.com

https://www.amazon.com/dp/B0BQHFXKHH

 

  • Original Volume One: Cancer Biology and Genomics for Disease Diagnosis

On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

This volume has the following three parts that are presented in the following order: A, C, B

Audio & Text

  • PART A: A1 and A2
  • PART C

followed by

Computer Graphics & Text

  • PART B – Graphics & Text
  • Appendix to PART B – Computer Code

Format detailed

PART A: Audio & Text

PART A.1: The eTOCs in Spanish in Audio format AND

PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Book in English in Audio format

PART B: Computer Graphics and English Text

The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format

Appendix to PART B – Computer Code

 

Volume Two

View on Amazon.com

https://www.amazon.com/dp/B0BQTM44SM

 
  • Original Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery 
    • On Amazon.com since 5/18/2017
    • http://www.amazon.com/dp/B071VQ6YYK
    •  
  •  NEW GENRE Volume Two Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

  • https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-two-cancer-therapies-metabolic-genomics-interventional-immunotherapy-and-nanotechnology-in-therapy-delivery-series-b-volume-2%ef%bf%bc/

  • Format detailed 
  • PART A: The eTOCs in Spanish in Audio format
  • PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
  • PART C: The Editorials of the original e-Book in English in Audio format

 

 

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

This page has the following sub pages.

  • NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis – Series C, Volume 1
  • NEW GENRE Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery – Series C, Volume 2

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,037 other subscribers
  • Recent Posts

    • Novartis and Bristol Myers Squibb halt CAR-T trial for autoimmune diseases over patient deaths: a potential issue with cell-based manufacturing September 15, 2026
    • FDA Contemplates Changes in Trial Design, Drug Development, and Use of AI in Clinical Trials September 15, 2026
    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


Loading Comments...
%d